Collectively, these processes are orchestrated by the constitutively active KRAS/ERK/ADAM17 signaling axis in CRC harboring KRAS mutations, which identifies Jagged1 as both a proteolytic substrate and a terminal effector of KRAS signaling. This evidence concerns the gene ADAM17 and colorectal carcinoma.